Fig. 3.
VMP001-ICMV immunization elicits antibodies with high avidity and broader specificity than soluble protein vaccination. C57Bl/6 mice were immunized with VMP001-ICMVs or soluble VMP001 (25 μg MPLA with 0.1 or 1 μg protein) as in Fig. 2 and avidity and specificity of sera were analyzed on day 90. (A) Avidity index of sera from immunized mice binding to whole VMP001 protein. (B) Anti-VMP001 IgG antibodies elicited with VMP001-ICMVs + MPLA (blue) or VMP001 + MPLA (red) were further analyzed for binding to fragments of VMP001, including the Type I insert, AGDRx5, Region I, Region II, C terminus, or a scrambled peptide negative control. Data represent the mean ± SEM of two independent experiments conducted with n = 3.